Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

The past decade has seen a revolution of new advances in the management of non-small
cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and …

It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts,
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …

Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 in: Journal of the
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …